Multiple sclerosis attracts hard supplement marketing, because one of its best-established risk factors is a nutrient you can buy in a capsule. The gap between risk epidemiology and treatment evidence is the whole story here, so the conclusion comes first.
Nothing Proco sells treats, prevents or modifies multiple sclerosis. Not our magnesium glycinate, not our omega-3, not our sleep or cognitive products. We do not currently sell a vitamin D product at all — we have written about what the vitamin D cognition and mood trials show, and that is as far as it goes. MS is diagnosed and managed by a neurologist using licensed medicines. No food supplement substitutes for that.
The UK guideline is explicit about a product we sell. NICE's guideline on multiple sclerosis in adults (NG220), recommendation 1.9.2: "Do not offer omega-3 or omega-6 fatty acid compounds to treat MS. Explain that there is no evidence that they affect relapse frequency or progression of MS." And 1.9.1: "Do not offer vitamin D solely for the purpose of treating MS." Both sentences stay in.
MS is a chronic inflammatory, demyelinating disease of the central nervous system: the immune system damages the myelin sheath around nerve fibres in the brain, spinal cord and optic nerves, with axonal and neuronal loss. The cause is not fully settled, but the evidence implicating Epstein-Barr virus is strong. In a cohort of over 10 million US military personnel, 955 of whom developed MS in service, risk of MS increased 32-fold after EBV infection, with no comparable increase after other viruses including cytomegalovirus.
The MS Society estimates over 150,000 people live with MS in the UK, with nearly 7,100 newly diagnosed each year, based on NHS primary care records. A UK primary-care analysis covering 1990 to 2010 found women accounted for 72% of prevalent and 71% of incident cases, with peak incidence at ages 40 to 50.
The textbook split into relapsing-remitting, secondary progressive and primary progressive courses is being retired clinically. The Association of British Neurologists' 2024 guidance states that "MS should be considered a single disease with relapsing and progressive components."
NG220 recommendation 1.1.5 says to refer anyone suspected of having MS "for diagnosis by a consultant neurologist or a specialist under their supervision." Recommendation 1.1.6, amended in 2026, says to "Diagnose MS using a combination of history, examination, MRI and laboratory findings, and by following the 2024 revised McDonald criteria."
Those criteria were published in The Lancet Neurology in 2025, the fifth revision since 2001. In the authors' summary: the optic nerve now counts as a fifth CNS location for lesions disseminated in space; the central vein sign, paramagnetic rim lesions and CSF kappa free light chain concentrations can be used, where available, as supportive evidence conferring specificity in specific situations; and in certain cases a radiologically isolated syndrome, or symptoms not amounting to a clear attack, can fulfil the criteria. There is new guidance for people aged 50 and over and those with comorbidities. The authors say the revisions "should expedite the diagnosis of multiple sclerosis, while maintaining specificity."
That last clause is contested: The Lancet Neurology published four correspondence pieces in 2026 raising concerns, plus a reply from the authors. Diagnosing earlier on more biomarkers also widens the scope for misdiagnosis.
One line is worth quoting. Recommendation 1.1.3: "Do not routinely suspect MS if a person's main symptoms are fatigue, depression, dizziness or vague sensory phenomena, unless they have a history or evidence of focal neurological symptoms or signs."
If fatigue and fuzzy thinking are the whole picture, the useful first move is usually the short list of blood tests worth asking for, not an MRI.
NG220 lists twelve licensed options for active relapsing-remitting MS, each via its own NICE technology appraisal — among them cladribine, ublituximab, ofatumumab, ocrelizumab, glatiramer acetate, the interferon betas, dimethyl fumarate and teriflunomide — plus further lists for highly active and rapidly evolving severe disease adding natalizumab, alemtuzumab and fingolimod. Siponimod is recommended for secondary progressive MS with evidence of active disease; ocrelizumab for early primary progressive MS with imaging features characteristic of inflammatory activity. The ABN guidance says "High efficacy therapy should be considered as the first option in eligible patients."
Now the part that usually gets flattened. These drugs suppress relapses and new lesions well, and disability accumulation much less well.
Even the relapsing trials had mixed secondaries: the Multiple Sclerosis Functional Composite favoured ocrelizumab in OPERA II (p=0.004) but not in OPERA I (p=0.33). These are real, worthwhile, licensed treatments — not cures, and in progressive disease the effect sizes are modest.
NG220 names two non-drug measures: "Encourage people with MS to exercise" (1.4.1), and "Advise people with MS not to smoke and explain that it will increase the progression of disability" (1.4.2). Both are worth sitting with: exercise outperforms supplements across most brain-health outcomes we have looked at, and stopping smoking has measurable neurological payback.
The risk evidence is genuinely strong. A prospective nested case-control study in US military personnel found that among white participants, each 50 nmol/L increase in serum 25-hydroxyvitamin D carried an odds ratio for MS of 0.59 (95% CI 0.36 to 0.97); the top quintile, above 99.1 nmol/L, had an OR of 0.38 (95% CI 0.19 to 0.75). The same study found no significant association among black and Hispanic participants — a null usually left out. A Mendelian randomisation study, which uses inherited variants to approximate lifelong exposure and is harder to confound, found each genetically determined one-standard-deviation decrease in log-transformed 25(OH)D conferred a 2.0-fold increase in the odds of MS (95% CI 1.7 to 2.5). Its authors concluded that "Whether vitamin D sufficiency can delay, or prevent, MS onset merits further investigation in long-term randomized controlled trials." Note what that is a claim about: who gets MS, not what happens after.
Those trials have now largely been run, and they do not show disease modification.
A 2026 systematic review of relapse rate and MRI activity across eleven primary studies concluded that "Current data does not support vitamin D as a disease-modifying therapy beyond correction of deficiency."
The closest thing to a prevention trial is VITAL, which randomised 25,871 US adults (men 50+, women 55+) to 2,000 IU/day vitamin D and/or 1,000 mg/day omega-3 for a median 5.3 years. Vitamin D reduced all incident autoimmune disease pooled — rheumatoid arthritis, thyroid disease, psoriasis and others — with a hazard ratio of 0.78 (95% CI 0.61 to 0.99, p=0.05). The omega-3 arm gave 0.85 (95% CI 0.67 to 1.08, p=0.19), not statistically significant. VITAL was not an MS trial, was not powered for MS, and enrolled an age group well past peak MS onset. It is not an MS prevention claim.
The Cochrane review of dietary interventions for MS-related outcomes, updated in 2020, covered 30 trials, every one at unclear or high risk of bias. Polyunsaturated versus monounsaturated fatty acids: relapse risk ratio 1.02 (95% CI 0.88 to 1.20), very low certainty. Omega-3 versus omega-6: relapse risk ratio 1.02 (95% CI 0.62 to 1.66), EDSS mean difference 0.00 (95% CI −0.30 to 0.30), and likely no difference in new gadolinium-enhancing lesions at moderate certainty. Antioxidants versus placebo: relapse risk ratio 0.98 (95% CI 0.59 to 1.64). The authors concluded "there is insufficient evidence to determine whether supplementation with antioxidants or other dietary interventions have any impact on MS-related outcomes."
NG220 says at 1.5.8: "Explain to people that there is no evidence that a specific diet will improve fatigue in people with MS, but that a healthy diet will benefit their general health."
The commercial temptation is obvious: point at the vitamin D risk epidemiology, which is strong, and let readers carry it to treatment. We are declining it. That association is about who develops MS, over decades, with early-life exposure appearing to matter most. It is not evidence that a capsule changes established disease — and four of the five trials above tested close to that question and returned null or negative primary endpoints.
If you have MS, the people to talk to about vitamin D are your neurologist and MS team, who can read your actual 25-hydroxyvitamin D result alongside everything else you take. Correcting a deficiency is a clinical decision, not a shopping one. And new neurological symptoms are a referral to a neurologist, not a supplement question.
We have no product here, and would rather say so than find a hook. That is the same bar we apply to everything we decline to stock.
This article is general information written on 18 October 2026. It is not medical advice, it cannot diagnose or treat anything, and it is not a substitute for a neurologist or your MS team. Nothing Proco sells treats, prevents or modifies multiple sclerosis.